Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.

CONCLUSIONS: These findings highlight the value of once-monthly paliperidone palmitate in the treatment of patients with schizophrenia. PMID: 27479694 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/27479694?dopt=Abstract

Source: Current Medical Research and Opinion - October 20, 2016 Category: Research Tags: Curr Med Res Opin Source Type: research

More News: Research